Novavax Executive and Leadership Team

Ian Watkins, the Executive Vice President & Chief Human Resources Officer at Novavax, directs all global human capital strategies. Overseeing talent acquisition, development, and retention, Watkins ensures the organization possesses the skilled workforce necessary to drive Novavax's mission of vaccine innovation. This leadership role involves fostering a culture of collaboration and scientific excellence, critical for advancing vaccine candidates against serious infectious diseases. By aligning HR initiatives with the company's strategic objectives, Ian Watkins supports the development and commercialization efforts for vaccines targeting COVID-19, influenza, and other critical pathogens. Watkins's oversight extends to compensation, benefits, and employee engagement programs, ensuring Novavax remains an employer of choice within the biotechnology sector and supports its global operational footprint.

Louis Fries, the Chief Medical Officer at Novavax, guides the company's clinical development and medical affairs strategy. Overseeing the design and execution of clinical trials, Fries ensures the rigorous evaluation of Novavax's vaccine candidates, including those for COVID-19, influenza, and respiratory syncytial virus. This critical role involves translating scientific discoveries into tangible health solutions, driving the advancement of the company's proprietary technology platform. By leading the medical teams, Louis Fries ensures adherence to global regulatory standards and ethical guidelines throughout the development process. The Chief Medical Officer's expertise is pivotal in shaping the clinical narrative and demonstrating the efficacy and safety of Novavax's innovative vaccine portfolio, supporting its mission to protect against serious infectious diseases worldwide.

Mark Casey, the Executive Vice President & Chief Legal Officer at Novavax, provides comprehensive legal counsel and oversees all corporate governance matters. Directing the legal department, Casey ensures Novavax operates in full compliance with international laws and regulations pertinent to biotechnology and vaccine development. This executive function is crucial for navigating complex licensing agreements, strategic partnerships, and intellectual property protection, safeguarding the company's innovative research and development efforts. By managing litigation and risk, Mark Casey supports the company's global commercialization initiatives and its mission to deliver life-saving vaccines. The Chief Legal Officer's strategic guidance is essential for maintaining Novavax's integrity and fostering trust with stakeholders across its worldwide operations.

Raburn Mallory, the Senior Vice President, Head of Clinical Development and Deputy Chief Medical Officer at Novavax, supports the strategic direction and operational execution of the company's clinical trials. Collaborating closely with the Chief Medical Officer, Mallory oversees the day-to-day management of clinical development programs, ensuring the efficient and effective progression of vaccine candidates through regulatory pathways. This leadership position is vital for translating Novavax's scientific advancements into investigational vaccines targeting critical infectious diseases, including COVID-19 and influenza. By driving the clinical development process, Raburn Mallory contributes directly to demonstrating the safety and immunogenicity of Novavax's proprietary recombinant protein nanoparticle vaccine technology. Mallory's role is integral to advancing the company's pipeline and fulfilling its commitment to global public health.